Irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 007)

Grossi, Francesco; Belvedere, Ornella; Rossetto, C.; Sibau, A.; Vigevani, Enrico; Recchia, Leonardo; Sacco, Chiara; Iop, Aldo; Tumolo, Salvatore; Fasola, Gianpiero

doi:10.1200/jco.2004.22.90140.7363

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, in our pilot study only two out of 10 patients developed grades 3 and 4 neutropenia without episodes of febrile neutropenia. Conversely, other studies [25,[28][29][30][31] using the same combination were associated with an increased incidence of myelosuppression. This difference may be explained by both the prophylactic use of rhG-CSF but, also, by the schedule of irinotecan administration (every 3 weeks in the present study as opposed to the weekly administration in the other studies).…”

Section: Discussionmentioning

confidence: 82%

“…This difference may be explained by both the prophylactic use of rhG-CSF but, also, by the schedule of irinotecan administration (every 3 weeks in the present study as opposed to the weekly administration in the other studies). A major disadvantage in our study as almost in every study using the same combination, irrespectively of the schedule chosen, is the high incidence of grades 3-4 diarrhea [25,26,[28][29][30][31]. Although, in the pilot study only 1 out of 10 patients experienced grade 3 diarrhea in total about 23% of the patients experienced such a toxicity.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study

et al. 2005

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 92%

Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study

et al. 2005

View full text Add to dashboard Cite

“…Docetaxel with or without irinotecan provides a similar benefit in terms of overall survival and response rate [28][29][30][31]. The associations irinotecan-docetaxel and irinotecan-gemcitabine, with or without the COX-2 inhibitor celecoxib, were assessed in a phase II randomised trial with four treatment arms: irinotecan 60 mg/m 2 plus docetaxel 35 mg/m 2 or irinotecan 100 mg/m 2 plus gemcitabine 1000 mg/m 2 , both with or without celecoxib 400 mg bid.…”

Section: Combination Chemotherapymentioning

confidence: 99%

Second and third line treatment in non-small cell lung cancer

Favaretto

Pasello

Magro

et al. 2009

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…The doublet appeared to improve QoL, but confirmation would be necessary before adopting this regimen, given multiple negative doublet trials second-line. Other trials explored the combination of docetaxel with gemcitabine, irinotecan, or vinorelbine and found them not superior to docetaxel alone, or the combination too toxic [32,[35][36][37][38][39][40][41][42][43][44][45]. Cytotoxic doublets are not considered a standard approach for the second-line or beyond treatment of advanced NSCLC.…”

Section: Combination Cytotoxic Therapiesmentioning

confidence: 99%

Second- and third-line treatments in non-small cell lung cancer

Kumar¹,

Wakelee²

2006

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Slow but steady progress has been made in the treatment of advanced non-small cell lung cancer. For first-line therapy, multiple chemotherapy combination therapies can extend survival and improve quality of life. And recently, for the first time ever, a noncytotoxic agent, the antivascular endothelial growth factor antibody bevacizumab, has been shown to improve survival when added to chemotherapy. Striking improvements have also been made in second-line treatment. In August 2004, only one agent was US Food and Drug Administration (FDA) approved in this setting, docetaxel, but by the beginning of 2005, two more were available, pemetrexed and erlotinib. All three of these drugs can significantly benefit patients, with 1-year survival in excess of 30%. Choosing between the three agents can be challenging, and this review focuses on the toxicity differences and predictors of response that can help guide this decision. Docetaxel and pemetrexed, both traditional intravenous cytotoxins, are excellent options for patients who have shown some response to first-line chemotherapy, but at this time, no other means exist to determine likelihood of response. When choosing between the two, pemetrexed causes significantly less neutropenia than does docetaxel, at least on the standard every-3-week regimen. With erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, there are factors that can predict for response, including little or no smoking history, and adenocarcinoma histology. Therefore, patients who fit these characteristics are good candidates for second-line erlotinib. However, the relationship between response to erlotinib and improved survival remains unclear, and several laboratory analyses that may help further, such as evaluation of EGFR gene copy number, are still under development. Although erlotinib is the only FDA-approved option currently available for third-line therapy, many patients with good performance status may benefit from third-line therapy and beyond. In addition to the approved second-line options, other single-agent chemotherapies to consider for treatment beyond second-line are gemcitabine, irinotecan, and oral topotecan. Many new drugs, including bevacizumab, ZD6474 (AstraZeneca, Wilmington, DE), sorafenib, cetuximab, paclitaxel poliglumex, epothilones, and others, alone or in combination with traditional agents, are currently undergoing investigation and hold great promise.

show abstract

Irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 007)

Cited by 3 publications

References 0 publications

Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study

Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study

Second and third line treatment in non-small cell lung cancer

Second- and third-line treatments in non-small cell lung cancer

Contact Info

Product

Resources

About